SIBN
SI-BONE, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.24
P/S
2.90
EV/EBITDA
-64.06
DCF Value
$38.31
FCF Yield
-1.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
79.6%
Operating Margin
-11.1%
Net Margin
-9.4%
ROE
-11.0%
ROA
-7.9%
ROIC
-10.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $56.4M | $-1.6M | $-0.04 |
| FY 2025 | $200.9M | $-18.9M | $-0.44 |
| Q3 2025 | $48.7M | $-4.6M | $-0.11 |
| Q2 2025 | $48.6M | $-6.2M | $-0.14 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.77
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.